Related by context. All words. (Click for frequent words.) 77 chronic eosinophilic leukemia 76 myelodysplastic myeloproliferative diseases 76 hypereosinophilic syndrome 73 MDS MPD 71 unresectable recurrent 70 HES CEL 69 Kit CD# positive 69 non splenectomized 68 Peginterferon alfa 2b 67 chronic immune thrombocytopenic 67 metastatic malignant 67 R Saizen R 67 subependymal giant cell 67 Ph + acute lymphoblastic 67 C1 Inhibitor 66 R lenalidomide 66 chronic idiopathic thrombocytopenic purpura 66 oropharyngeal candidiasis OPC 66 hyperphenylalaninemia HPA due 66 IMiDs ® compound 66 essential thrombocythemia ET 66 PEGylated anti 66 Investigational Treatment 65 SPRYCEL ® 65 Callisto initiated 65 leukemia AML 65 Hsp# Inhibitor 65 purpura ITP 65 IMiDs ® 65 TNF Tumor Necrosis Factor 65 c KIT 65 Pharmacokinetics PK 65 refractory chronic lymphocytic 65 ® lenalidomide 65 Zorbtive TM 65 Pegloticase 65 neutropenia dehydration dyspnea 64 Receives Orphan Drug Designation 64 Acute Myeloid Leukemia AML 64 receiving INTRON 64 Achieves Primary Endpoint 64 cutaneous T 64 metastatic dermatofibrosarcoma protuberans DFSP 64 sapropterin dihydrochloride 64 Patients Treated With 64 Initiates Clinical Trial 64 pediatric Crohn disease 64 leukemia ALL 64 insulin glulisine 64 refractory acute promyelocytic 64 Severe Sepsis 64 decompensated liver disease 64 BARACLUDE ® 64 PRN FDA Approves 64 polycythemia vera essential thrombocythemia 64 cell lymphoma CTCL 64 SNT-MC#/idebenone 64 Mg Uk 64 onset idiopathic hypogonadism 64 dasatinib Sprycel ® 64 non splenectomised 64 imatinib Gleevec ® 64 INSPIRE Trial Phase III 63 Heterozygous Familial Hypercholesterolemia 63 methylnaltrexone bromide 63 cetuximab Erbitux R 63 inhalation powder 63 discontinued Viread 63 hyaluronidase enzyme 63 exocrine pancreatic insufficiency EPI 63 gastrointestinal stromal tumors GISTs 63 Demonstrates Significant 63 Orally Active 63 AVN# Phase 63 Initiates Phase II 63 tumors GIST 63 PEGylated Fab fragment 63 Cutaneous T 63 Romiplostim 63 papillary renal cell carcinoma 63 Newly Diagnosed Multiple Myeloma 63 nucleoside analog 63 Completes Patient Enrollment 63 demonstrated antitumor activity 63 pediatric acute lymphoblastic 63 Amgen Neulasta R 63 thalidomide Thalomid 63 orally administered inhibitor 63 LHRH receptor positive 63 recurrent glioblastoma multiforme 63 FDA APPROVES 63 refractory acute myeloid 63 rheumatoid arthritis osteoarthritis ankylosing 63 AVAPRO 63 myeloproliferative diseases 63 haematopoietic stem cell 63 Myelodysplastic Syndrome MDS 63 lymphoid malignancies 63 Adjuvant Treatment 63 Vidaza azacitidine 63 diagnosed Ph + 63 Tigecycline 62 glucocorticoid induced osteoporosis 62 Lubiprostone 62 Meets Primary Endpoint 62 Long Term Efficacy 62 Initiates Phase III 62 refractory cutaneous T 62 non nucleoside inhibitor 62 humanized interleukin 6 62 Blinatumomab 62 autoantibody positive 62 Presents Preclinical Data 62 Bosutinib 62 IMiDs R 62 Predict Response 62 advanced metastatic renal 62 Begins Dosing 62 Orally administered 62 Drug Candidate 62 BUPHENYL 62 5 HT1A receptor 62 Phase 2b Clinical Trial 62 ADP receptor antagonist 62 metastatic gastric 62 Completes Enrollment 62 ergot derivatives 62 acid phosphatase PAP 62 Polyneuropathy 62 Initiates Clinical 62 Danazol 62 Recombinant Human 62 Granulocyte Colony Stimulating Factor 62 Sprycel dasatinib 62 Evoltra ® 62 vapreotide acetate 62 Luteinizing Hormone Releasing Hormone 62 Annamycin 62 FOLOTYN ® 62 MEK Inhibitor 62 Factor Receptor 62 Prolongs Survival 62 Vidaza ® 62 Chronic Idiopathic Constipation 62 Personalized Immunotherapy 62 K ras mutations 62 indinavir Crixivan 62 Neulasta R 62 Amgen Neulasta ® 62 thetreatment 62 sodium glucose cotransporter 62 Pfizer Camptosar 62 diarrhea predominant irritable 62 mitoxantrone plus 61 somatostatin analog 61 Novel Small Molecule 61 chronic HBV 61 Leukemias 61 Kuvan R 61 Amrubicin 61 Fludarabine 61 #/#mg 61 CYT# potent vascular disrupting 61 XL# XL# 61 Philadelphia Chromosome Positive 61 forodesine 61 Reminyl galantamine 61 metastatic neuroendocrine tumors 61 leukemia multiple myeloma 61 chronic myeloid 61 hyperplasia BPH 61 Ranolazine 61 Novel Oral 61 rheumatoid arthritis psoriatic arthritis 61 adalimumab Humira 61 Raptiva ® 61 novel emulsion formulation 61 Azacitidine 61 Soft Tissue Sarcoma 61 PNP inhibitor 61 stage IIIb IV 61 Initiates Enrollment 61 orally administered synthetic retinoid 61 Myelodysplastic syndromes 61 CYP#A# CYP#D# 61 idiopathic thrombocytopenic purpura ITP 61 Previously Treated 61 onset diabetes mellitus 61 alpha interferons 61 venlafaxine Effexor 61 receptor tyrosine kinase inhibitor 61 HBeAg negative 61 Fludara ® 61 leukemia CLL 61 haematologic malignancies 61 bladder ovarian 61 systemic juvenile idiopathic 61 Tyrosine Kinase Inhibitor 61 Clolar ® 61 mutated K ras 61 severe hepatic insufficiency 61 phase III isavuconazole 61 dasatinib Sprycel 61 Kamada AAT 61 targeted antifolate 61 MAGE A3 ASCI 61 lintuzumab SGN 61 psoriatic arthritis PsA 61 novel VDA molecule 61 non metastatic osteosarcoma 61 HBeAg positive patients 61 efalizumab 61 CLL SLL 61 vinca alkaloid 61 Improves Outcomes 61 Thiazolidinediones 61 Presents Preclinical 61 docetaxel Taxotere ® 61 Progressive Multifocal Leukoencephalopathy 61 selective modulator 61 elevated transaminases 61 MOVIPREP R 61 sorafenib tablets 61 denileukin diftitox 61 Shows Efficacy 61 BCG refractory carcinoma 61 TYGACIL 61 erlotinib Tarceva ® 61 Femara letrozole 61 Chronic lymphocytic leukemia CLL 61 Solorel TM 61 soluble tumor necrosis 61 headache abdominal pain 61 CALGB # [002] 61 Inhalation Aerosol 61 eosinophilic asthma 61 Desvenlafaxine 61 Lymphocytic 61 Tramiprosate ALZHEMED TM 60 Granted Orphan Drug 60 alfa 2a 60 ACOMPLIA R 60 GH deficiency 60 progressive PsA 60 dihydrochloride 60 See CLINICAL PHARMACOLOGY 60 sunitinib Sutent 60 Sebivo 60 gastrointestinal stromal tumors GIST 60 dalteparin 60 vWD 60 Adjunctive Therapy 60 relapsed ALL 60 Bezielle 60 HER2 overexpression 60 Nipent R 60 ABCB1 60 Hodgkin lymphoma HL 60 quetiapine Seroquel 60 oncolytic virus therapies 60 relapsed leukemia 60 Pramlintide 60 syngeneic 60 Elitek 60 Natalizumab 60 Pafuramidine 60 severe renal impairment 60 histone deacetylase HDAC inhibitor 60 topically administered 60 Mg Usa 60 Paraplatin ® 60 Romidepsin 60 refractory anaplastic astrocytoma 60 corticotropin injection 60 protease inhibitor PI 60 Submits Biologics License Application 60 Tanespimycin 60 FOR FURTHER INFORMATION ABOUT 60 cisplatin gemcitabine 60 hepatorenal syndrome 60 relapsed MM 60 Ribavirin causes 60 docetaxel Taxotere R 60 hematological parameters 60 rheumatoid arthritis inflammatory bowel 60 Demonstrates Potential 60 MPS VI 60 HBeAg + 60 BUPHENYL R 60 Tiuxetan 60 Geodon ziprasidone 60 selective phosphodiesterase 60 evaluating tivozanib 60 Vascular Inflammation 60 2 methoxyestradiol 60 treat chronic sinusitis 60 pravastatin Pravachol 60 Angiotensin Converting Enzyme 60 Phase IIa Trial 60 novel histone deacetylase 60 Vidaza R 60 sorafenib Nexavar 60 HDAC Inhibitor 60 endometriosis ovarian cysts 60 BCR ABL inhibitor 60 Acute Bacterial Sinusitis ABS 60 Upregulation 60 L Annamycin 60 Diabetic Neuropathy 60 Atypical Hemolytic Uremic Syndrome 60 Chronic Lymphocytic Leukemia CLL 60 bevacizumab Avastin ® 60 Kinoid 60 Antitumor Activity 60 gastrointestinal stromal tumors 60 reduce serum phosphate 60 Chronic Heart Failure 60 Raptiva R 60 metastatic colorectal carcinoma 60 markets HP Acthar 60 Myelodysplastic syndromes MDS 60 iobenguane 60 Certican 60 Allogeneic 60 aurora kinase 60 Vicriviroc 60 CEQ# 60 Reports Preclinical Data 60 GCase 60 Clevudine 60 acetonide FA 60 Dementia Related Psychosis 60 Gamunex C 60 controlled dose escalation 60 Immunotherapeutic 60 Paxil paroxetine 60 idiopathic thrombocytopenic purpura 60 Single Dose 60 peritumoral brain edema 60 Gonal f R 60 tryptase 60 IN PATIENTS WITH 60 Aryplase 60 circulating endothelial cells 60 Lymphoid 60 N acetylgalactosamine 6 60 fumarate 60 Presents Positive 60 beta 1a 60 lexidronam injection 60 CTAP# Capsules 60 REVLIMID lenalidomide 60 deletion 5q 60 depsipeptide 60 HERCEPTIN 60 aplastic anemia AA 60 e antigen HBeAg 60 tuberous sclerosis TS 60 peptibody 60 Certolizumab pegol 60 Inhalation Solution 60 atherothrombotic events 60 virus HCV infection 60 metastatic pancreatic 59 ORENCIA ® 59 CIMZIA TM certolizumab pegol 59 LAB CGRP 59 Prodarsan R 59 NS5b 59 Hepsera adefovir dipivoxil 59 pheochromocytoma 59 danazol 59 oncologic diseases 59 CTAP# 59 atopic asthma 59 vinorelbine tartrate 59 factor TNF receptor 59 Initiate Clinical Trial 59 dual endothelin receptor antagonist 59 pathophysiological effects 59 unresectable HCC 59 MYLOTARG 59 Kinase Inhibitor 59 Submits NDA 59 Cloretazine 59 PKC# 59 mild hepatic impairment 59 relapsing multiple sclerosis 59 Velcade bortezomib 59 aripiprazole Abilify 59 fosbretabulin 59 Multiple Ascending Dose 59 lymphomas leukemias 59 BEXXAR Therapeutic Regimen 59 haematological malignancies 59 pan HDAC inhibitor 59 Systemic Lupus Erythematosus SLE 59 Toxoid 59 benign prostatic hypertrophy BPH 59 biologic DMARD 59 melphalan prednisone 59 situ CIS 59 HIV coinfected 59 intranasal formulation 59 topoisomerase II inhibitor 59 number NCT# ClinicalTrials.gov 59 Patients Receiving 59 Mouse Models 59 Epratuzumab 59 chimeric monoclonal antibody 59 hoFH 59 GSTP1 59 everolimus tablets 59 IL# PE#QQR 59 gastrointestinal stromal tumor GIST 59 Teriflunomide 59 generation purine nucleoside 59 RoACTEMRA 59 Engerix B 59 finasteride Proscar 59 CCR5 receptor antagonist 59 Syndrome LEMS 59 liposomal formulation 59 Investigational Oral 59 Phase #b/#a clinical 59 Naive Patients 59 Irinotecan 59 trastuzumab Herceptin ® 59 cholesteryl ester transfer 59 Viread tenofovir disoproxil fumarate 59 multiple myeloma MM 59 Kuvan sapropterin dihydrochloride 59 antidepressants fluoxetine 59 Alfacell proprietary ribonuclease 59 Pivotal Phase III 59 KRAS mutations 59 Temsirolimus 59 mequinol 59 transthyretin amyloidosis 59 Familial Adenomatous Polyposis FAP 59 Gleevec resistant 59 Ozarelix 59 monoclonal antibody IgG1 Mab 59 Microplasmin 59 A1PI 59 developing Zerenex ferric 59 metastatic GIST 59 primary generalized tonic 59 CIMZIA R 59 desire disorder HSDD 59 hypoxia activated prodrug 59 Rebif interferon beta 1a 59 5 lipoxygenase inhibitor 59 Yondelis ® 59 familial amyloidotic polyneuropathy FAP 59 alefacept 59 Secondary Hyperparathyroidism 59 irreversible inhibitor 59 Vitrasert R 59 YONDELIS 59 basal bolus regimen 59 Cryopyrin Associated Periodic Syndromes 59 Tracleer bosentan 59 unstable angina UA 59 Respiratory Virus 59 G CSFs 59 metastatic castrate resistant 59 Chronic lymphocytic leukemia 59 R sorafenib tablets 59 Complicated Skin 59 metastatic colorectal 59 Angiox R 59 Myelodysplasia 59 Initiate Phase 59 LymphoStat B belimumab 59 GTC recombinant form 59 #:#-# [031] 59 active ankylosing spondylitis 59 Zavesca R 59 Fondaparinux 59 JAK2 Inhibitor 59 IgG1 monoclonal antibody 59 Chronic Myelogenous Leukemia 59 GARDASIL ® 59 Vitrasert ® 59 Stage IIIB IV 59 polycythemia vera PV 59 Lupus Nephritis 59 Phase IIb Clinical Trial 59 immune thrombocytopenic purpura 59 recurrent NSCLC 59 Castration Resistant Prostate Cancer 59 injectable bulking agent 59 Tumor Necrosis Factor 59 Demonstrates Positive 59 memantine HCl 59 alpha1 antitrypsin deficiency 59 #mg Tablets [002] 59 Oral Formulation 59 Cytotoxic T 59 GW# [003] 59 AMMONUL R 59 immune globulin intravenous 59 octreotide implant 59 Protease Inhibitors 59 Adenomas 59 Liprotamase 59 DNA demethylating agent 59 PDGFRA 59 Nucleoside 59 Anthracycline 59 LH FSH 59 hepatocellular carcinomas 59 potent inducer 59 EGFR HER2 59 Denufosol 59 HER2 positive metastatic breast 59 Xyrem ® 59 GABITRIL 59 Submits IND 59 azacytidine 59 ZOLINZA 58 Solesta TM 58 interferon gamma 1b 58 Noxafil 58 adefovir dipivoxil 58 orphan medicinal product 58 Tesmilifene 58 BUPHENYL R sodium phenylbutyrate 58 MKC# MT 58 ONCASPAR 58 Serostim ® 58 mecasermin 58 humanized anti 58 T2DM 58 Panzem R 58 Subtypes 58 juvenile idiopathic arthritis JIA 58 investigational immunotherapy 58 Epidermal Growth Factor Receptor 58 RhuDex R 58 Seliciclib 58 Antitumor 58 flutamide 58 Hycamtin ® 58 protein tyrosine phosphatase 1B 58 dual orexin receptor 58 Betaferon R 58 balsalazide disodium Capsules 58 Tarceva TM 58 pregabalin Lyrica 58 Saizen ® 58 Receive Milestone Payment 58 Receives Orphan Drug 58 PD LID 58 unresectable inoperable 58 Lambert Eaton Myasthenic 58 Uvidem 58 EGFr expressing metastatic colorectal 58 mutated KRAS gene 58 potently inhibit 58 Orphan Drug designations 58 oral ghrelin agonist 58 Cimzia TM 58 HCV Protease Inhibitor 58 PEGINTRON TM 58 Mimpara 58 Esbriet ® 58 SSc 58 IND Application 58 PGL# 58 receptor inhibiting monoclonal 58 prostanoid 58 Hervé Hoppenot President 58 Investigational Compound 58 Reduces Mortality 58 selective kinase inhibitor 58 nucleotide analog 58 recurrent metastatic 58 Onrigin 58 oxaliplatin Eloxatin 58 taxane resistant 58 patientswith 58 nonnucleoside reverse transcriptase inhibitors 58 Relapsed Refractory Multiple Myeloma 58 immunotherapeutic agent 58 FASLODEX 58 HIV HCV coinfected 58 antibody MT# 58 factor G CSF 58 inhibitor RG# 58 Oropharyngeal Candidiasis 58 Somatuline R Depot 58 Refractory Hodgkin Lymphoma 58 Initiates Phase 2b 58 directed radiotherapeutic antibody 58 Sudhir Agrawal D.Phil 58 Wafer polifeprosan 58 REBETOL combination therapy 58 CYP#A# substrate 58 HCV polymerase 58 recurrent epithelial ovarian 58 alkylating agent 58 Plaque Psoriasis 58 Methylnaltrexone 58 FLT3 mutations 58 RhuDex ™ 58 formerly LymphoStat B 58 CanAg 58 therapeutically inactive prodrug 58 TÎ ² 4 58 Fluconazole 58 radiation sensitizer 58 BioSante Pharmaceuticals Announces 58 SHPT 58 lucinactant 58 Shows Promise Against 58 Bronchopulmonary Dysplasia 58 rasagiline tablets 58 Metastatic Prostate Cancer 58 investigational atypical antipsychotic 58 Serostim R 58 Paliperidone Palmitate 58 RANK Ligand inhibitor 58 Acute myeloid leukemia 58 cinacalcet 58 LymphoStat B TM 58 MCSP respectively 58 standard chemotherapy regimen 58 primary dysmenorrhea 58 Riluzole 58 cMET 58 TAXOL 58 Campath alemtuzumab 58 Lispro 58 seronegative 58 targeting CD# 58 Apaziquone 58 plasma kallikrein inhibitor 58 subcutaneous immunoglobulin 58 ara C 58 rALLy clinical trial 58 Recurrent Glioblastoma 58 Successfully Completes Phase 58 Aviptadil 58 Mylan Receives Approval 58 calcineurin inhibitor 58 mTOR mammalian target 58 Orphan Drug status 58 Omacetaxine 58 castrate resistant prostate cancer 58 overt nephropathy 58 R roscovitine 58 Vectical 58 prokinetic agent 58 monoclonal anti 58 itraconazole Sporanox 58 direct renin inhibition 58 chills fever headache 58 castrate resistant 58 Glatiramer acetate 58 Synvisc ONE 58 Omalizumab 58 Known hypersensitivity 58 uremic pruritus 58 chronic thromboembolic pulmonary 58 induced macular edema 58 REYATAZ ® 58 2A receptor agonist 58 Microalbuminuria 58 Degarelix 58 toenail onychomycosis 58 thromboxane A2 58 ribavirin therapy 58 methylnaltrexone bromide subcutaneous injection 58 nilotinib Tasigna 58 R abatacept 58 Randomized Phase II 58 venlafaxine XR 58 receptor CXCR4 58 Neuroendocrine Tumors 58 III EGFRvIII 58 HBeAg negative patients 58 mitogen activated ERK kinase 58 chronic plaque psoriasis 58 lipid lowering agents 58 heparanase 58 treatmentof 58 HoFH 58 Multaq dronedarone 58 factor TNF 58 Phase IIb Trial 58 Initiates Phase 58 Bronchiectasis 58 HCV replicon 58 accumulate preferentially 58 alpha antagonist 58 Demonstrates Efficacy 58 Keppra ® levetiracetam 58 Posaconazole 58 SJIA 58 Merck Serono Nycomed 58 HepG2 cells 58 purified inactivated vaccine 58 Systemic Sclerosis 58 trastuzumab Herceptin R 58 BENLYSTA ® 58 treatment naive genotype 58 Aloxi ® 58 atypical hemolytic uremic syndrome 58 neurological manifestations 58 ovarian carcinoma 58 stable angina pectoris 58 kidney urologic 58 antibody MAb 58 Acute Myeloid Leukaemia AML 58 Hemodialysis Patients 58 Files IND 58 Therapeutic Vaccine 58 Gonal f 58 glutamic acid decarboxylase 58 TEMODAL 58 Gleevec Glivec 58 invasive candidiasis 58 histologically confirmed 58 serotonin norepinephrine reuptake inhibitor 58 paclitaxel Taxol R 58 luteinizing hormone releasing 58 Daclizumab 58 HeFH 58 paclitaxel Taxol ® 58 Oracea TM 58 histologic subtype 58 poor metabolizers 58 Files Investigational 58 anastrazole 58 Xcytrin R 58 systemically administered 58 anticholinergic agents 58 erythropoietic 58 Thalomid ® 58 FDA Accepts 58 unresectable locally advanced 57 Modrenal R 57 HuLuc# 57 Immune Thrombocytopenic Purpura ITP 57 octreotide acetate 57 HepDirect prodrug 57 Treating Chronic 57 Aflibercept 57 anti PlGF 57 Announces Poster Presentations 57 Anti Tumor 57 post herpetic neuralgia PHN 57 Novel Inhibitor 57 Novel Therapeutic 57 Postmenopausal 57 telomerase therapeutic 57 carcinoids originate 57 ThermoDox ® clinical 57 SUTENT ® 57 TRAIL R2 57 Launches Generic Version 57 etanercept Enbrel 57 severe hypersensitivity reactions 57 diabetic gastroparesis 57 Nonalcoholic fatty liver 57 hypoparathyroidism 57 VISICOL R 57 previously untreated follicular 57 binds selectively 57 pharmacologically active isomer 57 nonmetastatic 57 Gel repository corticotropin injection 57 Alemtuzumab 57 myelofibrosis polycythemia vera 57 diarrhea fatigue asthenia 57 Advanced Renal Cell 57 alvespimycin 57 omacetaxine mepesuccinate 57 refractory gout 57 acute GvHD 57 interleukin IL -# 57 TTR amyloidosis 57 M2 subunit 57 Sipuleucel T 57 TNF Blockers 57 Enzyme Replacement Therapy 57 arthritis PsA 57 cidofovir 57 bladder carcinoma 57 MAGE A3 protein 57 NRTI resistance 57 docetaxel Injection Concentrate 57 ADPKD 57 dextromethorphan quinidine 57 recombinant interferon 57 sublingual tablets 57 SUPPRELIN R LA 57 humanized monoclonal 57 Decitabine 57 OMP #R# 57 Fingolimod 57 cardiovascular calcification 57 hemorrhagic cystitis 57 microtubule inhibitor 57 UPLYSO 57 mild renal insufficiency 57 Pazopanib 57 DOXIL 57 severe oral mucositis 57 BiovaxID TM 57 Mouse Model 57 lipoglycopeptide 57 Severe Primary IGFD 57 treatment naïve genotype 57 Genentech Rituxan 57 myeloid metaplasia 57 lutropin alfa 57 Sevelamer 57 HBeAg positive 57 ALN HPN 57 DIFICID ™ 57 R bendamustine hydrochloride 57 Fx #A 57 administered concomitantly 57 methimazole 57 effector function 57 Sapacitabine 57 investigational humanized monoclonal antibody 57 basiliximab 57 Clinical Practice Guideline 57 sargramostim 57 rhIGF-I/rhIGFBP-3 57 advanced hepatocellular carcinoma 57 Cytarabine 57 vaginal candidiasis 57 TRIOLEX HE# APOPTONE HE# 57 systemic anaplastic large 57 Nexavar sorafenib 57 uricase 57 Transdermal Delivery 57 Receives Positive Opinion 57 BYETTA ® 57 Camptosar ® 57 orally bioavailable 57 PDX pralatrexate 57 HuMax 57 Shows Promising 57 THALOMID 57 Clinical Trial Evaluating 57 anthracycline containing 57 colorectal adenoma 57 FDA Okays 57 novel immunomodulatory 57 Platinol ® 57 acute myeloid 57 CCR5 delta# 57 Plecanatide 57 alpha1 antitrypsin AAT deficiency 57 Phase Ib IIa 57 LEUKINE 57 Atomoxetine 57 Troxatyl 57 AMEVIVE 57 mixed hyperlipidemia 57 Chronic Lung 57 SCIg 57 pancreatic prostate 57 adult chronic ITP 57 signal transduction inhibitors 57 mRCC 57 Prodrug 57 beta estradiol 57 acute myelogenous leukemia AML 57 acyclovir Lauriad R 57 histone deacetylase inhibitor 57 multicenter Phase II 57 REVLIMID R 57 Gleevec imatinib mesylate 57 Progenitor cells 57 Renal Impairment 57 derivatives Radilex TM 57 HCV SPRINT 57 Intravenous immunoglobulin 57 Carbamazepine 57 gastrin analogue TT 57 JAK Inhibitor 57 chemosensitizer 57 cell adhesion molecule 57 heavily pretreated 57 CLINICAL PHARMACOLOGY 57 Estrogen Receptor 57 metastatic hormone refractory 57 plasma pharmacokinetics 57 chorionic gonadotropin 57 NOMID 57 highly purified pasteurized 57 thrombin inhibiting aptamer 57 TYZEKA 57 visilizumab 57 C1 INH deficiency 57 TLR7 agonist 57 briakinumab 57 phase IIb trial 57 Torisel temsirolimus 57 pancreatic endocrine 57 metaglidasen 57 Gets FDA Clearance 57 Genasense ® oblimersen 57 Fc fusion protein 57 MTHFR 57 Warfarin Coumadin 57 Xyfid TM 57 NAGS deficiency 57 diabetic neuropathic pain 57 Hematologic 57 Hypogonadism 57 de novo AML 57 P2Y 57 Randomized Phase 57 retinoic acid receptor 57 tyrosine kinase inhibitor TKI 57 CAELYX 57 baminercept 57 metastatic renal 57 Reclast zoledronic acid 57 volociximab 57 Folfox 57 COPEGUS ribavirin 57 STELARA TM 57 Retinoic Acid 57 thyroid peroxidase 57 RhuDex TM 57 icatibant 57 nucleotide analogue 57 Cx# [002] 57 adenosine injection 57 Azmacort R 57 refractory NSCLC 57 trivalent inactivated influenza 57 Factor VIIa 57 demethylating agent 57 Crit Rev 57 Simulect 57 Bucindolol 57 Juvenile Idiopathic Arthritis JIA 57 CC genotype 57 uterine fibroids endometriosis 57 Novel Compound 57 myeloproliferative disorders 57 miconazole Lauriad ® 57 elotuzumab 57 #:#-# [023] 57 ARIKACE ™ 57 MORAb 57 refractory colorectal cancer 57 Vildagliptin 57 GATTEX ™ 57 Demonstrates Sustained 57 Cancidas 57 Prostate specific antigen 57 REVIVE Diabetes 57 Vandetanib 57 FOLFIRI alone 57 Aplidin R 57 xenograft models 57 acute intermittent porphyria 57 Hospital Acquired Pneumonia 57 Azedra 57 chronic HBV infection 57 anthracyclines taxanes 57 malignancy HCM 57 PDE# inhibitors 57 Somatuline Depot 57 Octreolin 57 Archexin 57 cromolyn sodium 57 BENICAR HCT 57 Campath ® 57 refractory chronic myeloid 57 Vaccine Adjuvant 57 ritonavir boosted protease inhibitor 57 myelodysplastic syndromes MDS 57 vWF 57 Gliadel R 57 vidofludimus 57 stage IIIB 57 GAMMAGARD 57 gemtuzumab ozogamicin 57 Shows Statistically Significant 57 virus HCV protease inhibitor 57 exocrine pancreatic insufficiency 57 Friedreich Ataxia FRDA 57 Chronic ITP 57 Interferon Alpha 56 mcg doses 56 Fabry Disease 56 dacarbazine DTIC